Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption
19.05.2022 - Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption VANCOUVER, May 19, 2022 (GLOBE NEWSWIRE) - Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) ...
United States Neither The Canadian Securities Exchange Canadian Securities Exchange Regulation Services Provider Frankfurt Stock Exchange About Clearmind
Source: wallstreet-online.de